HYDERABAD: In what may be a first, a high-level delegation from the US drug regulator US Food & Drug Administration, led by the commissioner, will Dr. Robert M. Califf on Tuesday visited the manufacturing facilities of Hyderabad-based active pharmaceutical ingredient (API) manufacturer Divi’s Laboratories.
Other members of the team included USFDA’s India Country Director Dr Sarah McMullen visited the company’s manufacturing facility at Choutuppal on the outskirts of Hyderabad in Telangana.
Divi’s Laboratories said it is demonstrating its world-class, large-scale manufacturing facilities, advanced automated manufacturing capabilities, commitment to innovation and its critical role in investing in new technologies to ensure a consistent supply of high-quality APIs.
The USFDA delegation also interacted with top management of Divi’s Laboratories, which supplies APIs to more than 100 countries.
The visit by the US drug regulator delegation covered a wide range of topics, reflecting the dynamic landscape of the API industry, integrating new technologies, sustainable practices in chemistry, raising manufacturing standards and ensuring availability of APIs.
“We are proud to participate in this important visit to share our role as a reliable API manufacturer that can deliver large quantities in a relatively short time,” said Dr. Kiran S. Divi., CEO, Divi’s Laboratories Limited. “We look forward to continuing to engage and be part of addressing critical issues impacting the global pharmaceutical industry,” he added.
Other members of the team included USFDA’s India Country Director Dr Sarah McMullen visited the company’s manufacturing facility at Choutuppal on the outskirts of Hyderabad in Telangana.
Divi’s Laboratories said it is demonstrating its world-class, large-scale manufacturing facilities, advanced automated manufacturing capabilities, commitment to innovation and its critical role in investing in new technologies to ensure a consistent supply of high-quality APIs.
The USFDA delegation also interacted with top management of Divi’s Laboratories, which supplies APIs to more than 100 countries.
The visit by the US drug regulator delegation covered a wide range of topics, reflecting the dynamic landscape of the API industry, integrating new technologies, sustainable practices in chemistry, raising manufacturing standards and ensuring availability of APIs.
“We are proud to participate in this important visit to share our role as a reliable API manufacturer that can deliver large quantities in a relatively short time,” said Dr. Kiran S. Divi., CEO, Divi’s Laboratories Limited. “We look forward to continuing to engage and be part of addressing critical issues impacting the global pharmaceutical industry,” he added.
ADVERTISEMENT
